US equities
|
MU
$953.22
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
MU
$953.22
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Inozyme Pharma, Inc. - Common Stock
(NQ:
INZY
)
4.000
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Inozyme Pharma, Inc. - Common Stock
< Previous
1
2
3
Next >
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
June 20, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
May 27, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
May 21, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 19, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders
May 18, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Synergy CHC Corp. (NASDAQ: SNYR) Reports Strong Q1, Signals 2025 Expansion in GLP-1 and Global Markets – More Stocks Inside
May 16, 2025
Via
AB Newswire
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
May 16, 2025
From
Halper Sadeh LLC
Via
Business Wire
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
May 16, 2025
From
Ademi & Fruchter LLP
Via
Business Wire
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 14, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
April 10, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
March 10, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
February 21, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
January 10, 2025
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at Upcoming Investor Conferences
November 11, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 05, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
October 24, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
October 17, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
October 07, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
September 26, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
August 29, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 06, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
July 25, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
July 02, 2024
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
June 21, 2024
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
May 23, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
